Structure–activity relationships of 4-N-substituted ferroquine analogues: Timeto re-evaluate the mechanism of action of ferroquine

Journal of Organometallic Chemistry (Impact Factor: 2.17). 03/2009; 694(6):845. DOI: 10.1016/j.jorganchem.2008.09.033


A series of five new alkyl 4-N-substituted analogues of ferroquine (FQ, SR97193) were designed, synthesized,
and characterized. The antimalarial activity of the compounds was measured against twelve strains
of Plasmodium falciparum. The compounds were more active than chloroquine (CQ) against all the CQresistant
clones. For a better understanding of their mechanism of action, their physicochemical properties
(lipophilicity and basicity) and their action on the inhibition of b-hematin formation were evaluated.
The importance of the intramolecular hydrogen bond in neutral FQ in the antimalarial activity was
probed, compared to the methyl analogue 1.
Results of additional physicochemical measurements suggested new insights into the mechanism of
action of FQ in sharp contrast with CQ. We complement here our understanding on the mechanism of
action of FQ with the process of catalysis-mediated hemozoin formation at the interface between vacuolar
content and membrane lipids.

Download full-text


Available from: Natascha Leleu-Chavain, Oct 07, 2015
1 Follower
31 Reads
  • Source
    • "In order to assess the synergy of AVA with QN, 25 μl of AVA per well and 200 μl of the suspension of synchronous parasitized red blood cells (final parasitaemia, 0.5%; final haematocrit, 1.5%) per well were plated in 96-well plates containing the QN concentrations. The in vitro isotopic micro-test used had been previously described [34]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Quinine (QN) remains the first line anti-malarial drug for the treatment of complicated malaria in Europe and Africa. The emergence of QN resistance has been documented. QN resistance is not yet a significant problem, but there is an urgent need to discover partners for use in combination with QN. The aim of the study was to assess the in vitro potentiating effects of atorvastatin (AVA), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, in combination with QN against Plasmodium falciparum and to evaluate whether the effects of AVA could be associated with gene copy number or mutations in genes involved in QN resistance, such as pfcrt, pfmdr1, pfmrp and pfnhe. The susceptibilities to combination of AVA with QN were assessed against 21 parasite strains using the in vitro isotopic microtest. Genotypes and gene copy number were assessed for pfcrt, pfmdr1, pfmdr2, pfmrp genes. In addition, the number of DNNND, DDNHNDNHNN repeats in pfnhe-1 ms4760 and the ms4760 profile were determined for each strains of P. falciparum. AVA demonstrated synergistic effects in combination with QN against 21 P. falciparum strains. The QN IC50 was reduced by 5% (0% to 15%; 95%CI: 1%-8%), 10% (3% to 23%; 95%CI: 7%-14%) and 22% (14% to 40%; 95%CI: 19%-25%) in presence of AVA at concentrations of 0.1, 0.5 and 1.0 microM, respectively. These reductions were all significant (p < 0.009). The reduction in the QN IC50 in presence of AVA was not significantly correlated with the QN IC50 (r = 0.22, P = 0.3288) or the AVA IC50 (r = 0.03, P = 0.8946). The synergistic effect of AVA in combination with QN was not significantly associated with polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe-1 genes that could be involved in QN resistance. The synergistic effect of AVA on QN responses was not significantly associated with pfmdr1 copy number (P = 0.0428). The synergistic effect of AVA in combination with QN was found to be unrelated to mutations occurring in transport protein genes involved in QN drug resistance. The different mechanisms of drug uptake and/or mode of action for AVA compared to the other anti-malarial drugs, as well as the AVA-mediated synergy of the anti-malarial effect of QN, suggests that AVA will be a good candidate for combinatorial malaria treatment. All of these observations support calls for both an in vivo evaluation with pharmacokinetic component and clinical trials of AVA as an anti-malarial therapy.
    Malaria Journal 05/2010; 9(1):139. DOI:10.1186/1475-2875-9-139 · 3.11 Impact Factor
  • Source
    • "The enhanced lipophilicity of 1 (P o/w 5 5.0) and 2, compared with 3 (P o/w 5 4.4), could also play a role. Recent studies suggest that the activity of ferroquine results, at least in part, from its superior lipophilicity compared with chloroquine, and possibly from its localization in the lipidic sites of heme crystallization [Biot et al., 2009]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The ferrocenyl diphenol 1 [1,1-bis(4-hydroxyphenyl)-2-ferrocenyl-but-1-ene] displays strong cytotoxic effects against a variety of cancer cells. In the present study we have evaluated the immunomodulatory and antiparasitic activities of compound 1 and its protected dipalmitate analogue 2. We have furthermore compared the antiparasitic results of 1 and 2 with the organic analogue, 3 [1,1-bis(4-hydroxyphenyl)-2-phenyl-but-1-ene], where the ferrocenyl group has been replaced by a phenyl ring. When assayed against normal (noncancerous) splenocytes, all compounds were considered nontoxic. Compound 1 inhibited NO production by macrophages, inhibited concanavalin A-induced lymphoproliferation, and was active against Leishmania amazonensis and Trypanosoma cruzi. Compound 2 had lower activity in all assays performed. Surprisingly, compounds 1 and 2 exhibited similar and significant activity against Plasmodium falciparum, with IC50 values of 3.50 and 1.33 µM, respectively. Compound 3 showed an inverse activity profile, being active against T. cruzi but far less active against P. falciparum. Drug Dev Res 71: 69–75, 2010. © 2009 Wiley-Liss, Inc.
    Drug Development Research 01/2010; 71(1):69 - 75. DOI:10.1002/ddr.20349 · 0.77 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ferroquine (FQ or SR97193) is a novel antimalarial drug candidate, currently in development at Sanofi-Aventis. In contrast to conventional drugs, FQ is the first organometallic drug: a ferrocenyl group covalently flanked by a 4-aminoquinoline and a basic alkylamine. FQ is able to overcome the CQ resistance problem, an important limit to the control of Plasmodium falciparum, the principal causative agent of malaria. After fifteen years of effort, it is now possible to propose a multifactorial mechanism of action of FQ by its capacity to target lipids, to inhibit the formation of hemozoin and to generate reactive oxygen species.
    Molecules 02/2008; 13(11):2900-7. DOI:10.3390/molecules13112900 · 2.42 Impact Factor
Show more